U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H12FN3O4.H2O
Molecular Weight 275.2337
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TEZACITABINE

SMILES

O.NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)\C2=C/F

InChI

InChIKey=XPYQFIISZQCINN-QVXDJYSKSA-N
InChI=1S/C10H12FN3O4.H2O/c11-3-5-8(16)6(4-15)18-9(5)14-2-1-7(12)13-10(14)17;/h1-3,6,8-9,15-16H,4H2,(H2,12,13,17);1H2/b5-3+;/t6-,8+,9-;/m1./s1

HIDE SMILES / InChI

Description

Tezacitabine is a cytidine derivative patented by Merrell Dow Pharmaceuticals, Inc. as an antineoplastic and antiviral agent. Tezacitabine acts as irreversible ribonucleotide reductase inhibitor and DNA chain terminator. Tezacitabine shows as potent activity in a broad spectrum of tumor cell lines and in vivo tumor models, including human colon, prostate, and breast tumor xenografts, In clinical trials combination of Tezacitabine and 5-Fluorouracil exerts favor influences in patients with advanced solid tumors particularly in patients with esophageal and other gastrointestinal carcinomas.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
150-350 mg/m^2 on Day 1 of a 14-day cycle
Route of Administration: Intravenous